Medicaid dominates coverage of Novo, Lilly weight-loss drugs

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound.

U.S. government health plans account for the lion’s share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.